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Abstract
Background: Diagnostic tests are generally used in situations with similar pre-test probability of disease to where they 
were developed. When these tests are applied in situations with very different pre-test probabilities of disease, it is 
informative to model the likely implications of known characteristics of test performance in the new situation. This is 
the case for automated Mycobacterium tuberculosis (MTB) liquid culture systems for tuberculosis case detection which 
were developed and are widely used in low burden settings but are only beginning to be applied on a large scale in 
high burden settings.
Methods: Here we model the performance of MTB liquid culture systems in high and low tuberculosis (TB) prevalence 
settings using detailed published data concentrating on the likely frequency of cross-contamination events.
Results: Our model predicts that as the TB prevalence in the suspect population increases there is an exponential 
increase in the risk of MTB cross-contamination events expected in otherwise negative samples, even with equivalent 
technical performance of the laboratories. Quality control and strict cross-contamination measures become 
increasingly critical as the burden of MTB infection among TB suspects increases. Even under optimal conditions the 
realistically achievable specificity of these systems in high burden settings will likely be significantly below that 
obtained in low TB burden laboratories.
Conclusions: Liquid culture systems can play a valuable role in TB case detection in laboratories in high burden 
settings, but laboratory workers, policy makers and clinicians should be aware of the increased risks, independent of 
laboratory proficiency, of cross-contamination events in high burden settings.
Background
Automated liquid culture for M. tuberculosis (MTB) is
widely used in industrialized countries and increases the
sensitivity and reduces the time required for culture
based tuberculosis (TB) diagnosis. The use of this highly
sensitive technique increases the importance of robust
protocols and quality control to prevent and if this occurs
detect laboratory cross-contamination. Protocols and
quality control systems have been developed over the
past years that are adequate to ensure excellent perfor-
mance in settings with a low burden of TB. With the
recent trends in TB diagnostics for high burden countries
moving towards more modern technologies and scale-up
of laboratories for the implementation of new methods,
we and others in the field have expressed concern about
the feasibility and viability of these changes in certain
locations [1,2]. Laboratories in high burden TB areas that
perform diagnosis based on conventional microscopy are
now for example recommended to move towards innova-
tive liquid culturing systems for case detection and
molecular line probe assays for drug susceptibility test-
ing. These new technologies are more sensitive and rapid,
but the concern is that they are also more prone to labo-
ratory cross-contamination potentially resulting in misdi-
agnosis. This is especially problematic when these tests
are performed in laboratories with inadequate infrastruc-
ture and maintenance, or laboratories that lack the possi-
bility of confirmatory tests. This is often the case in
countries with a high TB burden. The consequences of a
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Page 2 of 5high contamination risk are numerous, but essentially
results in bacterial culture results from true negative
samples becoming positive. This issue forms the focus of
our study. As the treatment of TB patients is long and
complex with the potential for side effects, a false-posi-
tive MTB test is not trivial and places a significant burden
on the TB suspect, the suspect's family and the health
system in general [3,4].
Many studies have investigated the risks, causes and
consequences of laboratory cross-contamination both in
low- and high burden TB settings. However, the effect of
the prevalence of positive MTB samples in the laboratory
- which is strongly associated with the TB prevalence in
the area - is generally not explicitly considered with
respect to the absolute risk of cross-contamination of a
true negative sample. The aim of this study is to model
how cross-contamination risk, in laboratories with differ-
ent performance, is influenced by the rate of samples pos-
itive for MTB processed in the laboratory for liquid
culture.
Methods
First, a mathematical model is used to calculate the risk of
a negative sample being tested false-positive based on
various assumptions. It is assumed that the false positive
rate (FPR) and false negative rate (FNR) are constant
within a laboratory and depend only on the laboratory's
performance. The variable factor under investigation is
the prevalence of positive MTB samples (PSP) in the
tested batch of samples, which influences the chance that
a cross-contamination event will result in sample con-
tamination with mycobacteria.
To determine the variables at stake a diagnostic 2 × 2
table is used (Table 1).
This theoretical framework provides us with the follow-
ing variables:
- False positive rate (number of false positive samples
divided by total number of positive samples) is F = FP/p
- False negative rate (number of false negative samples
divided by total number of negative sample) is G = FN/q
The risk of a negative sample being tested falsely posi-
tive (called R) is calculated by dividing the false-positive
samples (the false-positive rate times the positive TB
samples) by the sum of the false positive and true nega-
tive samples; in a formula this is:
The number of true negative samples can be derived
from the negative samples minus the false-negative sam-
ples (the false-negative rate times the negative samples).
The new formula then becomes:
This formula can be applied to a wide array of different
laboratory settings, ranging from laboratories with a very
low FPR, FNR and PSP to laboratories with a very high
FPR, FNR and PSP. Regarding the variables required, it
should be noted that data on FPR and PSP are readily
available from various field studies. In contrast, the FNR
can not easily be measured in practice, since the gold
standard is liquid culture. Thus we are in fact modelling
the performance of the gold standard test. If we assume
an increased FNR (G) for liquid culture, the effect will be
an increase of R in the formula. Here we prefer to utilize
the most conservative model minimizing R. Therefore,
we assume that the FNR is zero (G = 0), creating the fol-
lowing simplified formula:
In reality of course there will be a small portion of false-
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Table 1: Diagnostic 2 × 2 Table
Reality
+ -
Liquid culture + TP FP p
- FN TN q
A standard diagnostic 2 × 2 table visualizes the results of performing a diagnostic liquid culture test on a batch of samples from MTB suspects. 
Since liquid culture is the gold standard, the results are hypothetically compared to reality. The letters indicate different sample categories; 
TP true positive, FP false positive, FN false negative, TN true negative. p is number of samples tested positive by liquid culture, q is number of 
samples tested negative by liquid culture.
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We used published study data from real-life laboratory
settings to explore the implications of this formula. A
study on culture cross-contamination rates in Dutch lab-
oratories provides data representing situations with a low
prevalence of TB and low levels of cross contamina-
tion[5]. In that study, all culture results of the TB national
reference laboratory (NRL) were investigated over a
seven-year period (1993 until 2000). The Dutch laborato-
ries sent on average 1570 culture samples per year to the
NRL, of which 21 were tested culture-positive by the
NRL, leading to a mean PSP of 21/1570 = 0.0134 = 1.34%.
Since the formula reflects rates, the number of positive
and negative samples (p and q) can be replaced by the
rate of positive and negative samples compared to the
total number of samples in a batch (PSP and 1-PSP). The
NRL also typed all positive TB cultures using DNA fin-
gerprinting. It was estimated, that the FPR in this time
period was 2.4% on average, ranging from 3.9% at the
start to 1.1% at the end of the investigation. It should be
noted, that the very low FPR of 1.1% (F = 0.011) was
reached after cross-contamination investigations had
been performed in the Dutch laboratories and advice had
been given about how to minimize the FPR over a num-
ber of years. We assume this extremely low FPR to repre-
sent the maximum practically achievable specificity of
the test under ideal conditions.
Using the above-mentioned data from the Dutch study,
the risk of a negative sample becoming falsely positive
can be calculated as followed:
This is the risk of a negative sample being cross-con-
taminated with a positive sample for a given FPR and PSP
(1.1% and 1.34%, respectively). When the FPR in the labo-
ratory is kept constant, but the prevalence of positive
MTB samples increases, the relation between positive
sample prevalence and cross-contamination risk can be
visualized as shown in figure 1 (dashed line). It can be
seen that the risk rises exponentially when the positive
sample prevalence rises (upper graph).
In another published study, a South-African laboratory
reported data representing a laboratory with a very high
FPR and PSP[6]. In that study an average of 1186 culture
samples per year were tested in the laboratory of which
55% were culture positive (PSP = 0.55, p = 1186 * 0.55 =
652). The FPR was reported to be 7.3% at the beginning of
the study and after implementation of specific interven-
tions it decreased to 2.1%. In order to model a broad
range of realistic situation in this case we use the initial
high FPR (F = 0.073) reported in the formula, the risk of
contamination of a true negative culture can be calcu-
lated as follows:
With a constant FPR and increasing or decreasing the
prevalence of positive TB samples in the South African
laboratory, the relating contamination risks are depicted
in figure 1 (solid line). Again, an exponential relation is
seen between PSP and contamination risk.
Considering that a PSP of up to 55% does occur in high
burden labs such as the South African laboratory, the part
of the graph that is considered to represent a realistic sit-
uation is enlarged in figure 1 (lower graph). It is clear that
when the FPR in a laboratory is kept constant, the risk of
a sample getting cross-contaminated rises exponentially
R =
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Figure 1 Calculated risk of a negative patient sample being test-
ed false positive due to cross contamination (Y axis) for different 
prevalence rates of positive MTB samples (X axis) showing the ef-
fect of the different laboratory cross contamination rates - 1.1% 
(dashed line) and 7.3% (solid line). The upper graph shows the ex-
ponential effect of the prevalence of true positives on contamination 
risk and the low graph shows an enlarged view of the clinically relevant 
area of the curve from the upper graph.
 
van Kampen et al. BMC Infectious Diseases 2010, 10:93
http://www.biomedcentral.com/1471-2334/10/93
Page 4 of 5when the positive sample rate in the tested batch rises.
Critically with a slightly raised FPR and high PSP this
effect can quickly become a serious issue.
Discussion
When applying diagnostic tests developed for use in situ-
ations with a very different pre-test probability of disease,
it is informative to model the likely implications on spe-
cific aspects of test performance in the new situation. In
this report we model the likely performance of M. tuber-
culosis automated liquid culture systems in high-burden
countries.
Our calculations of the expected performance of liquid
culture in different settings show that a laboratory with
optimized procedures that achieves a low FPR (e.g. 1.1% -
as for the Dutch laboratories) constitutes a low risk for a
MTB negative TB suspect sample becoming contami-
nated, even when a high proportion of true positives are
tested. When a contamination risk of 2.5% is taken as cut-
off value (meaning that a higher contamination risk for a
true negative sample is unacceptable, equivalent to a
greater than 1 in 40 chance of a negative sample being
falsely called positive), the PSP in a laboratory with a FPR
of 1.1% due to cross-contamination needs to increase to
over 60% in order for the contamination risk to rise above
the cut-off value. Fortunately, a PSP of over 60% is
unlikely in most countries. However, if the FPR is 7.3% -
as for the South African laboratory when liquid culture
was initially introduced -, the 2.5% cut-off value for con-
tamination risk of a negative sample is reached when the
PSP gets to 26%. With a FPR of 2.1% the PSP must reach
55% before the contamination risk of a true negative sam-
ple reaches 2.5%.
Over the previous years detailed and careful work has
accurately defined the primary concern with automated
liquid culture systems for the detection of M. tuberculosis
infection. Namely, as a consequence of the comparatively
rapid growth achieved and their excellent sensitivity they
are more sensitive to sample cross-contamination than
previous methods. We focused on this issue in this
report. Once this problem is recognized the impact can
be assessed and minimized. This results in a marked
increase in performance in the years following adoption
of the methods as well as the need for sufficient through-
put and investment to maintain laboratory skills. Of
course even in the best laboratories some level of cross-
contamination is inevitable and is this report we aimed to
be quite conservative regarding the likely cross contami-
nation rates. In industrialized countries with functioning
quality systems and active reference laboratory support
this level appears to be around 1% of all positive samples
[5].
The cross-contamination risk for true negative samples
is not only dependent on a laboratories performance
(mostly measured by FPR), but is also strongly influenced
by the MTB PSP in the laboratory. Unfortunately, as our
calculations demonstrate, the implications for even rela-
tively low levels of cross-contamination are much more
serious in locations with high TB prevalence in suspects.
These laboratories are ironically at present often the least
equipped to fully implement all the required protocols.
These precautions include: separating the processing of
non-sterile specimens and specimen with a high risk of
contamination (e.g. specimen of known positive cultures,
proficiency-test samples or contaminated culture vials);
using individual aliquots of buffer solution; uncapping
only one tube at a time; leaving samples at rest for five
minutes after centrifugation or mixing; decreasing the
maximum number of samples processed in one batch; re-
enforcing hygiene protocols and clean laboratory practice
among staff; and raising awareness and cautiousness of
the possibility of false-positive results in general [7-9]. In
order to monitor the performance of TB culture based
diagnostic programs it is also useful to have the facility to
genetically type a proportion of isolated strains, a service
which is also frequently unavailable were it is most
needed [10].
It has to be noted that in this study only the risk of
cross-contamination leading to false-positive case detec-
tion is discussed. Like in most studies, the research arti-
cles used here focus on calculating the false-positive
culture rate, i.e. the proportion of positive samples that is
false-positive for the presence of MTB. However, they do
not take into account the possible risk of a positive MTB
culture sample being cross-contaminated with another
positive sample, or the risk of a positive sample being
contaminated with a (multi-)drug resistant MTB sample.
The first event could potentially alter the Mycobacterium
tuberculosis family type and lead to errors in determining
epidemiological patterns. The latter could lead to a misdi-
agnosis of drug susceptibility of a sample and conse-
quently to a patient receiving an incorrect treatment
regimen. Thus, laboratory cross-contamination can also
lead to erroneous detection of (multi-)drug resistance
outbreaks or other epidemiological outbreaks. Since this
study does not measure the risks of these other cross-
contamination events, nor the effect that MTB positive
sample rate might have on these risks, it is suggested that
future studies also focus on these factors.
Conclusions
It can be concluded that even if future global laboratory
interventions are able to optimize the culture procedures
leading to similar low false-positive culture rates in all
laboratories around the world, the mathematical model
described in this study predicts that the risk of contami-
nation of negative cultures will inevitably remain higher
in areas with a higher TB prevalence. It is likely that alter-
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tics. Therefore, it is of critical importance that clinicians
and policy makers involved in TB diagnostics remain
aware of the possibility of laboratory cross-contamina-
tion, and take into account the regional differences when
interpreting results and potential of these highly sensitive
culture methods.
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